Since its creation in 2011, the Canadian Network for Observational Drug Effect Studies (CNODES) has built a network of over 100 scientists to ensure the safety and effectiveness of drugs for Canadians. CNODES has obtained access to administrative healthcare data on millions of medication users across Canada and internationally. CNODES uses state of the art methods of observational research, as well as rapid-response studies using semi-automated tools and a common data model (CDM) for standardized analyses.
Current Publications
Exposure to Valsartan Products Containing Nitrosamine Impurities in the United States, Canada, and Denmark
Pharmacoepidemiol Drug Saf. 2024 Sep;33(9):e5849.
Risk of Arterial and Venous Thrombotic Events Among Patients with COVID-19: A Multi-National Collaboration of Regulatory Agencies from Canada, Europe, and United States
Clin Epidemiol. 2024 Feb 10;16:71-89.
Prescription ranitidine use and population exposure in 6 Canadian provinces, 1996 to 2019: a serial cross-sectional analysis
CMAJ Open. 2023;11(6):E1033-E1040.
Validity of diagnoses of SARS-CoV-2 infection in Canadian administrative health data: a multiprovince, population-based cohort study
CMAJ Open. 2023;11(5):E790-E798.
Project Findings
Use of Oral Fluoroquinolones in Canada: A Drug Utilization Study Update
Fluoroquinolone use declined in the outpatient setting between 2008 and 2002, and findings suggest that the 2017 Health Canada regulatory actions could have affected their prescribing
Safety of Monitoring During Use of Ozempic in People with Diabetes: A CDM Pilot Project
Ongoing
Effectiveness of PCSK9 Inhibitors in Familial Hypercholesterolemia: Feasibility Study
Ongoing